Geode Capital Management’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $32.3M | Buy |
890,886
+71,446
| +9% | +$2.44M | ﹤0.01% | 1881 |
|
|
2026
Q1 | $27.1M | Sell |
819,440
-10,013
| -1% | -$424K | ﹤0.01% | 1834 |
|
|
2025
Q4 | $38.4M | Sell |
829,453
-6,928
| -0.8% | -$290K | ﹤0.01% | 1648 |
|
|
2025
Q3 | $29.3M | Buy |
836,381
+56,138
| +7% | +$1.95M | ﹤0.01% | 1803 |
|
|
2025
Q2 | $23.1M | Buy |
780,243
+14,709
| +2% | +$420K | ﹤0.01% | 1889 |
|
|
2025
Q1 | $22.9M | Sell |
765,534
-4,947
| -0.6% | -$151K | ﹤0.01% | 1833 |
|
|
2024
Q4 | $22.1M | Sell |
770,481
-5,098
| -0.7% | -$169K | ﹤0.01% | 1912 |
|
|
2024
Q3 | $30M | Buy |
775,579
+5,464
| +0.7% | +$195K | ﹤0.01% | 1753 |
|
|
2024
Q2 | $24.8M | Buy |
770,115
+36,567
| +5% | +$1.27M | ﹤0.01% | 1816 |
|
|
2024
Q1 | $28.5M | Buy |
733,548
+2,282
| +0.3% | +$79.8K | ﹤0.01% | 1714 |
|
|
2023
Q4 | $22.5M | Buy |
731,266
+20,382
| +3% | +$511K | ﹤0.01% | 1836 |
|
|
2023
Q3 | $15.9M | Buy |
710,884
+21,190
| +3% | +$483K | ﹤0.01% | 1965 |
|
|
2023
Q2 | $14.8M | Buy |
689,694
+46,506
| +7% | +$1.06M | ﹤0.01% | 2055 |
|
|
2023
Q1 | $15.4M | Buy |
643,188
+24,271
| +4% | +$644K | ﹤0.01% | 1971 |
|
|
2022
Q4 | $14.4M | Buy |
618,917
+13,225
| +2% | +$267K | ﹤0.01% | 2002 |
|
|
2022
Q3 | $9.7M | Buy |
605,692
+2,306
| +0.4% | +$40.7K | ﹤0.01% | 2283 |
|
|
2022
Q2 | $10.7M | Sell |
603,386
-7,219
| -1% | -$121K | ﹤0.01% | 2205 |
|
|
2022
Q1 | $12.4M | Buy |
610,605
+5,468
| +0.9% | +$103K | ﹤0.01% | 2198 |
|
|
2021
Q4 | $11.3M | Sell |
605,137
-5,456
| -0.9% | -$106K | ﹤0.01% | 2362 |
|
|
2021
Q3 | $12.1M | Sell |
610,593
-11,609
| -2% | -$251K | ﹤0.01% | 2331 |
|
|
2021
Q2 | $14.7M | Buy |
622,202
+35,927
| +6% | +$830K | ﹤0.01% | 2190 |
|
|
2021
Q1 | $13.9M | Buy |
586,275
+60,587
| +12% | +$1.44M | ﹤0.01% | 2116 |
|
|
2020
Q4 | $10.5M | Buy |
525,688
+19,627
| +4% | +$383K | ﹤0.01% | 2142 |
|
|
2020
Q3 | $10.5M | Sell |
506,061
-1,902
| -0.4% | -$34.3K | ﹤0.01% | 1911 |
|
|
2020
Q2 | $8.89M | Buy |
507,963
+20,055
| +4% | +$393K | ﹤0.01% | 1987 |
|
|
2020
Q1 | $7.97M | Buy |
487,908
+62,765
| +15% | +$1.3M | ﹤0.01% | 1879 |
|
|
2019
Q4 | $8.75M | Buy |
425,143
+17,798
| +4% | +$297K | ﹤0.01% | 2103 |
|
|
2019
Q3 | $4.68M | Buy |
407,345
+4,461
| +1% | +$50.9K | ﹤0.01% | 2421 |
|
|
2019
Q2 | $5.3M | Buy |
402,884
+39,748
| +11% | +$532K | ﹤0.01% | 2347 |
|
|
2019
Q1 | $5.5M | Buy |
363,136
+45,687
| +14% | +$732K | ﹤0.01% | 2275 |
|
|
2018
Q4 | $5.45M | Buy |
317,449
+31,301
| +11% | +$536K | ﹤0.01% | 2168 |
|
|
2018
Q3 | $4.22M | Buy |
286,148
+59,743
| +26% | +$1.06M | ﹤0.01% | 2459 |
|
|
2018
Q2 | $5.4M | Buy |
226,405
+25,096
| +12% | +$617K | ﹤0.01% | 2277 |
|
|
2018
Q1 | $5.14M | Buy |
201,309
+9,675
| +5% | +$231K | ﹤0.01% | 2217 |
|
|
2017
Q4 | $3.54M | Buy |
191,634
+14,589
| +8% | +$209K | ﹤0.01% | 2422 |
|
|
2017
Q3 | $1.86M | Buy |
177,045
+6,576
| +4% | +$72.5K | ﹤0.01% | 2804 |
|
|
2017
Q2 | $2.13M | Buy |
170,469
+23,901
| +16% | +$236K | ﹤0.01% | 2698 |
|
|
2017
Q1 | $1.47M | Buy |
146,568
+4,866
| +3% | +$72.3K | ﹤0.01% | 2818 |
|
|
2016
Q4 | $2.21M | Buy |
141,702
+36,133
| +34% | +$601K | ﹤0.01% | 2576 |
|
|
2016
Q3 | $2.03M | Buy |
105,569
+20,148
| +24% | +$239K | ﹤0.01% | 2551 |
|
|
2016
Q2 | $1.01M | Buy |
85,421
+6,518
| +8% | +$108K | ﹤0.01% | 2897 |
|
|
2016
Q1 | $1.43M | Buy |
78,903
+33,783
| +75% | +$614K | ﹤0.01% | 2674 |
|
|
2015
Q4 | $1.24M | Buy |
45,120
+7,133
| +19% | +$150K | ﹤0.01% | 2787 |
|
|
2015
Q3 | $839K | Buy |
+37,987
| New | +$687K | ﹤0.01% | 2962 |
|
Other funds holding COLL
JT
EAM
Geode Capital Management's COLL Position: Q2 2026 in Review
Geode Capital Management increased its Collegium Pharmaceutical (COLL) stake by 8.7% in Q2 2026, buying an estimated $2.44M and bringing the position to 890,886 shares worth $32.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1881.
Geode Capital Management first reported a position in COLL in Q3 2015 and has held it in 44 quarters since. The position peaked at $38.4M in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.
- Geode Capital Management held 890,886 shares of Collegium Pharmaceutical worth $32.3M as of Q2 2026.
- Geode Capital Management bought 71,446 Collegium Pharmaceutical shares in Q2 2026, an estimated $2.44M.
- Collegium Pharmaceutical made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1881 holding.
- Geode Capital Management first reported a position in Collegium Pharmaceutical in Q3 2015 and has held it in 44 quarters since.
- Geode Capital Management's Collegium Pharmaceutical position peaked at $38.4M in Q4 2025.
- 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.